This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The InvestorPlace Best ETFs for 2018 contest has officially hit its midway point, and we’re seeing some separation among the contestants. A few of the exchange-traded funds are struggling to reach breakeven while several are handily outpacing the S&P 500, as represented by the SPRD S&P 500 ETF (NYSEARCA:SPY). That fund garnered about 2% in the first six months.
SBIO QQQ SPY PHO QCOM
Stocks across the globe have suffered their worst first half in a year since 2010, wiping out trillions of dollars from the MSCI’s 47-country world index. A combination of tariff tantrums, broad tech sell-off, the prospect of end to the cheap money era and cooling growth in many parts of the economy including Europe and Japan resulted in huge capital outflows from the market. Additionally, the strength in the U.
AGG IVV VEA SHV VOO SPY EZU IVV EFA FLOT EEM
Geopolitical tensions, oil price movement and President Trump’s announcements hit the headlines in the month of May. Donald Trump made impactful announcements pertaining to deregulations, trade relations with other countries and sanctions against countries like Iran and Venezuela. Overall, markets remained upbeat barring some occasional dips.
AGG IVV ELY QQQ IEF VOO SPY EZU IVV IWM EEM
SPDR S&P 500 ETF TRUST Table of Contents Semi-Annual Report March 31, 2018 SPDR®
The month of April was mixed with earnings showing promise and broader markets returning decent returns despite rising yields and trade tensions. Oil has been on an uptrend. Overall, SPDR S&P 500 ETF (SPY - Free Report) gained about 3.5% in a month’s time (as of Apr 27, 2018), SPDR Dow Jones Industrial Average ETF (DIA - Free Report) rose 2.9% while Nasdaq-100-bsed ETF PowerShares QQQ ETF (QQQ - Free Report) jumped 4.
AGG IVV IEMG DIA SPY IVV EFA FLOT SHY IEFA
The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is the oldest U.S. ETF. Having launched in 1993, SPY recently celebrated its 25th birthday and it remains the largest ETF. SPY’s $259 billion in assets are more than $100 billion greater than that of its closest rival, the iShares Core S&P 500 ETF (NYSEARCA:IVV), which has $144 billion. A large asset base helps an index fund track its index with precision. SPY also offers tremendous liquidity with nearly $25 billion in daily dollar volume compared to $1.
IVV VOO SPY IVV
U.S. equity funds witnessed outflows of about $10.3 billion in March, per an etf.com article, citing FactSet data. Investors pulled out $22.1 billion of large-cap focused funds. The outflows chart was led by SPDR S&P 500 ETF Trust (SPY - Free Report) and iShares Core S&P 500 ETF (IVV - Free Report) , which witnessed a respective $12.2 billion and $9.8 billion in outflow in March.
NKTR BLT XPO BHPBF SPY IVV AMZN BHP AAPL BBL MSFT BHP IVV BHPLF FANG
The markets were more tensed than relaxed in the first quarter of 2018. Increasing inflationary expectations and rising rate fears pushed up bond yields and spurred equity sell-offs in late January and early February. Then, Trump-induced trade fear (thanks to his announcement of import tariffs) and a tech rout in March did the rest of the damage (read: 5 Reason Why FANG ETFs Lost Their Charm in March).
VEA VOO IEMG SPY EFA IEFA EEM
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
2018-07-06 - Asif
Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...
Silicon Investor Message Boards
This table lists all message boards related to SPY / SPDR S&P 500 ETF Trust on message board site Silicon Investor.
as of ET